Triparanol: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 1: | Line 1: | ||
{{Short description|A cholesterol-lowering drug withdrawn from the market}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002679 | |||
| IUPAC_name = 1-(4-Chlorophenyl)-4-(2-(dimethylamino)ethoxy)phenyl)-2-phenylbutan-1-ol | |||
| image = Triparanol.svg | |||
| width = 200px | |||
}} | |||
'''Triparanol''' was a cholesterol-lowering drug that was introduced in the 1950s and withdrawn from the market in the early 1960s due to adverse effects. It was marketed under the brand name MER/29. | |||
Triparanol was | ==History== | ||
Triparanol was developed by the pharmaceutical company [[Merrell Dow Pharmaceuticals|Merrell]] in the late 1950s. It was one of the first drugs designed to lower cholesterol levels in the blood. The drug was approved for use in the United States in 1959. | |||
== Mechanism of Action == | ==Mechanism of Action== | ||
Triparanol works by inhibiting the enzyme [[desmosterol]] _24-reductase, which is involved in the biosynthesis of [[cholesterol]]. By blocking this enzyme, triparanol reduces the conversion of desmosterol to cholesterol, thereby lowering cholesterol levels in the body. | |||
==Adverse Effects== | |||
Despite its initial promise, triparanol was found to have significant adverse effects. Patients taking the drug experienced a range of side effects, including [[cataracts]], [[skin lesions]], and [[gastrointestinal]] disturbances. The most serious side effect was the development of cataracts, which led to the drug's withdrawal from the market. | |||
== | ==Withdrawal== | ||
Due to the severe side effects, triparanol was withdrawn from the market in 1962. The withdrawal highlighted the importance of thorough drug testing and monitoring for adverse effects. | |||
The | ==Legacy== | ||
The case of triparanol is often cited in discussions about drug safety and the importance of post-marketing surveillance. It also led to increased scrutiny of cholesterol-lowering drugs and contributed to the development of safer alternatives. | |||
== | ==Related pages== | ||
* [[Cholesterol]] | |||
* [[Desmosterol]] | |||
* [[Pharmaceutical industry]] | |||
[[Category:Withdrawn drugs]] | |||
[[Category:Cholesterol-lowering agents]] | |||
[[Category: | |||
[[Category:Cholesterol]] | |||
Revision as of 11:54, 9 February 2025
A cholesterol-lowering drug withdrawn from the market
Triparanol was a cholesterol-lowering drug that was introduced in the 1950s and withdrawn from the market in the early 1960s due to adverse effects. It was marketed under the brand name MER/29.
History
Triparanol was developed by the pharmaceutical company Merrell in the late 1950s. It was one of the first drugs designed to lower cholesterol levels in the blood. The drug was approved for use in the United States in 1959.
Mechanism of Action
Triparanol works by inhibiting the enzyme desmosterol _24-reductase, which is involved in the biosynthesis of cholesterol. By blocking this enzyme, triparanol reduces the conversion of desmosterol to cholesterol, thereby lowering cholesterol levels in the body.
Adverse Effects
Despite its initial promise, triparanol was found to have significant adverse effects. Patients taking the drug experienced a range of side effects, including cataracts, skin lesions, and gastrointestinal disturbances. The most serious side effect was the development of cataracts, which led to the drug's withdrawal from the market.
Withdrawal
Due to the severe side effects, triparanol was withdrawn from the market in 1962. The withdrawal highlighted the importance of thorough drug testing and monitoring for adverse effects.
Legacy
The case of triparanol is often cited in discussions about drug safety and the importance of post-marketing surveillance. It also led to increased scrutiny of cholesterol-lowering drugs and contributed to the development of safer alternatives.
